mRNA for Antibody Manufacturing
In collaboration, Charles River Lab and Vernal Biosciences released this scientific poster. Since its release, new advancements have been made and new data is available to share. Join the webinar on December 12 to dive into this new data and hear from the researchers directly.
Clinical Trial: mRNA COVID-19 & Influenza Vaccines
A randomized clinical trial found that the simultaneous administration of mRNA COVID-19 and inactivated influenza vaccines has similar safety and reactogenicity compared to sequential administration. These findings support offering both vaccines at the same time, providing a convenient option for patients without added risk.
Lung Disease: LNPs Used for mRNA Delivery
This article describes that LNPs with zwitterionic polymer–lipid conjugates (ZIP-LNPs) offer a breakthrough for inhaled mRNA delivery to treat lung diseases. This approach improves LNP stability during nebulization, enhances mRNA delivery in mice, and shows good tolerance with no lung inflammation, making it a promising solution for overcoming traditional LNP limitations.
QbD for mRNA Quality Insights
Learn new strategies, explore a compelling case study, and gain actionable insights for your mRNA work, in this session—packed with scientific value. Christian Cobaugh, Founder and Chief Scientific Officer, presents this webinar discussing key quality attributes of mRNA and LNPs essential for improving drug efficacy and safety.
Versatile Tool for Tracking RNA Dynamics
This study shows that to study RNA biology in vivo, researchers have developed a bioluminescent platform using RNA tags that recruit luciferase fragments, enabling sensitive imaging without the limitations of fluorescence. This method allows single-copy RNA detection in cells and live animals, providing a versatile tool for tracking RNA dynamics at various scales.
LNPs Enhanced Immune Cell Infiltration
This article showcases the challenges glioblastoma (GBM) immunotherapy faces due to its tumor-friendly microenvironment, but LNPs carrying TLR agonists like pIpC show promise. These formulations activate immune cells, enhance cancer cell phagocytosis, and improve survival in models, suggesting potential for GBM treatments when optimized with other therapies like temozolomide or immune checkpoint inhibitors.
Future of mRNA Medicines
This study states mRNA-based drugs have advanced significantly, showing promise in immunotherapy and other treatments due to their unique advantages and improved delivery systems. This review explores the progress, challenges, and future prospects of mRNA medicines, highlighting factors like patient-specific variations and strategies to balance immune responses for optimal therapeutic outcomes.